nach oben

Journal of Cardiovascular Translational Research

Erschienen in:

30.01.2017 | Original Article

Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data

verfasst von: M. Alejandra Restrepo-Cordoba, Oscar Campuzano, Tomás Ripoll-Vera, Marta Cobo-Marcos, Irene Mademont-Soler, José M Gámez, Fernando Dominguez, Esther Gonzalez-Lopez, Laura Padron-Barthe, Enrique Lara-Pezzi, Luis Alonso-Pulpon, Ramon Brugada, Pablo Garcia-Pavia

Erschienen in: Journal of Cardiovascular Translational Research | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

This study sought to determine the usefulness of genetic testing to predict evolution in hypertrophic cardiomyopathy (HCM) and to assess the role of genetic testing in clinical practice. Genetic results of 100 HCM patients tested for mutations in ≥10 HCM-causing genes were evaluated. Patients were classified as with poor (group A) or favourable (group B) clinical course. Forty-five pathogenic mutations (PM) were identified in 28 patients (56 %) from group A and in 23 (46 %) from group B (p = 0.317). Only 40 patients (40 %) exhibited PM that had been previously reported and only 15 (15 %) had PM reported in ≥10 individuals. PM associated with poor prognosis were identified in just five patients from group A (10 %). Genetic findings are not useful to predict prognosis in most HCM patients. By contrast, real-world data reinforce the usefulness of genetic testing to provide genetic counselling and to enable cascade genetic screening.

Nur mit Berechtigung zugänglich

Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014). Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. Journal of the American College of Cardiology, 64(1), 83–99.CrossRefPubMed

Maron, B. J., Maron, M. S., & Semsarian, C. (2012). Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. Journal of the American College of Cardiology, 60(8), 705–715.CrossRefPubMed

Garcia-Pavia, P., Vázquez, M. E., Segovia, J., Salas, C., Avellana, P., Gómez-Bueno, M., et al. (2011). Genetic basis of end-stage hypertrophic cardiomyopathy. European Journal of Heart Failure, 13(11), 1193–1201.CrossRefPubMed

Li, Q., Gruner, C., Chan, R. H., Care, M., Siminovitch, K., Williams, L., et al. (2014). Genotype-positive status in patients with hypertrophic cardiomyopathy is associated with higher rates of heart failure events. Circulation. Cardiovascular Genetics, 7(4), 416–422.CrossRefPubMed

Ho, C. Y., Charron, P., Richard, P., Girolami, F., Van Spaendonck-Zwarts, K. Y., & Pinto, Y. (2015). Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovascular Research, 105(4), 397–408.CrossRefPubMedPubMedCentral

Landstrom, A. P., & Ackerman, M. J. (2010). Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. Circulation, 122(23), 2441–2449.CrossRefPubMed

Ho, C. Y. (2010). Genetics and clinical destiny: improving care in hypertrophic cardiomyopathy. Circulation, 122(23), 2430–2440.CrossRefPubMedPubMedCentral

Watkins, H., McKenna, W. J., Thierfelder, L., Suk, H. J., Anan, R., O’Donoghue, A., et al. (1995). Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. The New England Journal of Medicine, 332(16), 1058–1064.CrossRefPubMed

Ripoll-Vera, T., Gámez, J. M., Govea, N., Gómez, Y., Núñez, J., Socías, L., et al. (2016). Clinical and prognostic profiles of cardiomyopathies caused by mutations in the troponin T gene. Revista Española de Cardiología, 69(2), 149–158.CrossRefPubMed

10.

Calore, C., De Bortoli, M., Romualdi, C., Lorenzon, A., Angelini, A., Basso, C., et al. (2015). A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life. Journal of Medical Genetics, 52(5), 338–347.CrossRefPubMed

11.

García-Pavía, P., Segovia, J., Molano, J., Mora, R., Kontny, F., Erik Berge, K., et al. (2007). High-risk hypertrophic cardiomyopathy associated with a novel mutation in cardiac myosin-binding protein C. Revista Española de Cardiología, 60(3), 311–314.CrossRefPubMed

12.

Van Driest, S. L., Ackerman, M. J., Ommen, S. R., Shakur, R., Will, M. L., Nishimura, R. A., et al. (2002). Prevalence and severity of “benign” mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation, 106(24), 3085–3090.CrossRefPubMed

13.

Page, S. P., Kounas, S., Syrris, P., Christiansen, M., Frank-Hansen, R., Andersen, P. S., et al. (2012). Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. Circulation. Cardiovascular Genetics, 5(2), 156–166.CrossRefPubMed

14.

Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., et al. (2014). ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 35(39), 2733–2737.CrossRefPubMed

15.

García-Giustiniani, D., Arad, M., Ortíz-Genga, M., Barriales-Villa, R., Fernández, X., Rodríguez-García, I., et al. (2015). Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chain. Heart, 101(13), 1047–1053.CrossRefPubMedPubMedCentral

16.

Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., et al. (2011). ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. Circulation, 124(24), e783–e831.CrossRefPubMed

17.

Cuenca S, Ruiz-Cano MJ, Gimeno-Blanes JR, Jurado A, Salas C, Gomez-Diaz I, et al. (2016) Inherited Cardiac Diseases Program of the Spanish Cardiovascular Research Network (Red Investigación Cardiovascular) Genetic basis of familial dilated cardiomyopathy patients undergoing heart transplantation. The Journal of Heart and Lung Transplantation 35(5):625–635

18.

Charron, P., Dubourg, O., Desnos, M., Bennaceur, M., Carrier, L., Camproux, A. C., et al. (1998). Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation, 97(22), 2230–2236.CrossRefPubMed

19.

Lopes, L. R., Rahman, M. S., & Elliott, P. M. (2013). A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart, 99(24), 1800–1811.CrossRefPubMed

20.

Biagini, E., Olivotto, I., Iascone, M., Parodi, M. I., Girolami, F., Frisso, G., et al. (2014). Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy. The American Journal of Cardiology, 114(5), 769–776.CrossRefPubMed

21.

Girolami, F., Ho, C. Y., Semsarian, C., Baldi, M., Will, M. L., Baldini, K., et al. (2010). Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. Journal of the American College of Cardiology, 55(14), 1444–1453.CrossRefPubMed

22.

Gajendrarao, P., Krishnamoorthy, N., Selvaraj, S., Girolami, F., Cecchi, F., Olivotto, I., et al. (2015). An investigation of the molecular mechanism of double cMyBP-C mutation in a patient with end-stage hypertrophic cardiomyopathy. Journal of Cardiovascular Translational Research, 8(4), 232–243.CrossRefPubMed

23.

Santos, S., Marques, V., Pires, M., Silveira, L., Oliveira, H., Lança, V., et al. (2012). High resolution melting: improvements in the genetic diagnosis of hypertrophic cardiomyopathy in a Portuguese cohort. BMC Medical Genetics, 19, 13–17.

24.

Bottillo, I., D’Angelantonio, D., Caputo, V., Paiardini, A., Lipari, M., De Bernardo, C., et al. (2016). Molecular analysis of sarcomeric and non-sarcomeric genes in patients with hypertrophic cardiomyopathy. Gene, 577(2), 227–235.CrossRefPubMed

25.

Claes, G. R., van Tienen, F. H., Lindsey, P., Krapels, I. P., Helderman-van den Enden, A. T., Hoos, M. B., et al. (2016). Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. European Heart Journal, 37(23), 1815–1822.CrossRefPubMed

26.

Pasipoularides, A. (2015). Linking genes to cardiovascular diseases: gene action and gene-environment interactions. Journal of Cardiovascular Translational Research, 8(9), 506–527.CrossRefPubMedPubMedCentral

27.

Ackerman, M. J., Van Driest, S. V., Ommen, S. R., Will, M. L., Nishimura, R. A., Tajik, A. J., et al. (2002). Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T gene in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. Journal of the American College of Cardiology, 39(12), 2042–2048.CrossRefPubMed

28.

Ingles, J., McGaughran, J., Scuffham, P. A., Atherton, J., & Semsarian, C. (2012). A cost-effectiveness model of genetic testing for the evaluation of families with hypertrophic cardiomyopathy. Heart, 98(8), 625–630.CrossRefPubMed

29.

Barriales-Villa, R., Gimeno-Blanes, J. R., Zorio-Grima, E., Ripoll-Vera, T., Evangelista-Masip, A., Moya-Mitjans, A., et al. (2016). Plan of action for inherited cardiovascular diseases: synthesis of recommendations and action algorithms. Revista Española de Cardiología, 69(3), 300–309.CrossRefPubMed

30.

Boletín Oficial de la Comunidad de Madrid de 10 de Septiembre de 2013 [Accessed 5 Dec 2015]. Available at: http://w3.bocm.es/boletin/CM_Orden_bocm/2013/09/10/BOCM-20130910-1.pdf.

31.

Boletín Oficial de las Islas Baleares de 21 de Julio de 2014. [Accessed 5 Dec 2015]. Available at: http://www.caib.es/eboibfront/pdf/es/2014/89/875477

32.

Murphy, S. L., Anderson, J. H., Kapplinger, J. D., Kruisselbrink, T. M., Gersh, B. J., Ommen, S. R., et al. (2016). Evaluation of the Mayo Clinic phenotype-based genotype predictor score in patients with clinically diagnosed hypertrophic cardiomyopathy. Journal of Cardiovascular Translational Research, 9(2), 153–161.CrossRefPubMedPubMedCentral

Titel: Usefulness of Genetic Testing in Hypertrophic Cardiomyopathy: an Analysis Using Real-World Data
verfasst von: M. Alejandra Restrepo-Cordoba
Oscar Campuzano
Tomás Ripoll-Vera
Marta Cobo-Marcos
Irene Mademont-Soler
José M Gámez
Fernando Dominguez
Esther Gonzalez-Lopez
Laura Padron-Barthe
Enrique Lara-Pezzi
Luis Alonso-Pulpon
Ramon Brugada
Pablo Garcia-Pavia
Publikationsdatum: 30.01.2017
Verlag: Springer US
Erschienen in: Journal of Cardiovascular Translational Research / Ausgabe 1/2017
Print ISSN: 1937-5387
Elektronische ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-017-9730-8

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Impaired Tissue Oxygenation in Metabolic Syndrome Requires Increased Microvascular Perfusion Heterogeneity

Serum miR-92a-3p as a New Potential Biomarker for Diagnosis of Kawasaki Disease with Coronary Artery Lesions

Non classical Monocytes Levels, Increased by Subcutaneous Fat-Secretome, Are Associated with Less Rehospitalization after Heart Failure Admission

Minimally Invasive Adipose Graft Transposition Procedure